China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to advance the development of motixafortide, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC) in China. This partnership underscores GenFleet’s commitment to bringing innovative oncology therapies to Chinese patients.
Clinical Trial Details
GenFleet will fully fund, design, and execute a randomized Phase IIb clinical trial involving approximately 200 patients with PDAC. The trial will evaluate the efficacy and safety of motixafortide in combination with an anti-PD-1 therapy and chemotherapy, compared to chemotherapy alone. This study builds on previous positive data from a Phase IIa trial combining motixafortide with Keytruda (pembrolizumab) and chemotherapy against PDAC.
Drug Profile and Mechanism
Motixafortide is a CXCR4 inhibitor that has demonstrated its ability to mobilize hematopoietic stem cells into the bloodstream, a critical step in preparing for autologous bone marrow transplants. The drug is currently preparing for a New Drug Application (NDA) filing with the US FDA based on positive results from a Phase III study. BioLineRx retains all global rights to motixafortide, while GenFleet will be eligible for tiered percentage royalties on future sales in China if the drug receives approval.-Fineline Info & Tech
